/
ANIK
$15.01-$0.09 (-0.60%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$200.9M
13M shares
52-week range
$7.87 – $16.24
85% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-28.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105.6M | $114.6M | $130.5M | $147.8M | $113.8M | $120.8M | $119.9M | $112.8M |
| Cost of revenue | $31.3M | $28.7M | $61.4M | $64.9M | $40.6M | $38.3M | $43.9M | $49.0M |
| Gross profit | $74.3M | $85.9M | $69.0M | $82.9M | $73.2M | $82.5M | $76.0M | $63.8M |
| Gross margin | 70.4% | 74.9% | 52.9% | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% |
| R&D | $18.2M | $16.7M | $23.4M | $27.3M | $18.3M | $21.8M | $25.5M | $25.8M |
| Operating income | $21.7M | $34.2M | −$28.3M | $2.6M | $3.7M | $844.0K | −$5.1M | −$11.1M |
| EBITDA | $27.7M | $40.2M | −$1.0M | −$4.2M | $18.8M | $17.4M | $5.4M | −$3.6M |
| Net income | $18.7M | $27.2M | −$24.0M | $4.1M | −$14.9M | −$82.7M | −$56.4M | −$10.9M |
| Net margin | 17.7% | 23.7% | -18.4% | 2.8% | -13.1% | -68.4% | -47.0% | -9.6% |
| EPS (diluted) | 1.27 | 1.89 | -1.69 | 0.28 | -1.02 | -5.64 | -3.83 | -0.76 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $119M | $-0.12 | $-0.12–$-0.12 | 1 |
| 2027 | $127M | $0.15 | $0.15–$0.16 | 1 |
| 2028 | $134M | $0.66 | $0.66–$0.66 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.40
Price
$15.01
Implied downside
-97%
Peer comparison
Anika Therapeutics Inc
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
www.anika.com- Employees
- 235
- IPO / List date
- May 3, 1993
- HQ
- BEDFORD, MA
Held by traders on TradeandTell
No one on the platform currently holds ANIK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 502,217 | $7.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANIK yet.
